Filing Details

Accession Number:
0001209191-17-008356
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-02-07 16:31:50
Reporting Period:
2017-02-03
Filing Date:
2017-02-07
Accepted Time:
2017-02-07 16:31:50
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1598646 Minerva Neurosciences Inc. NERV Pharmaceutical Preparations (2834) 260784194
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1610384 Remy Luthringer C/O Minerva Neurosciences, Inc.
1601 Trapelo Road, Suite 284
Waltham MA 02451
President & Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-02-03 32,096 $4.71 32,096 No 4 M Direct
Common Stock Disposition 2017-02-03 32,096 $11.02 0 No 4 S Direct
Common Stock Acquisiton 2017-02-06 2,185 $4.71 2,185 No 4 M Direct
Common Stock Disposition 2017-02-06 2,185 $11.00 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2017-02-03 32,096 $0.00 32,096 $4.71
Common Stock Stock Option (Right to Buy) Disposition 2017-02-06 2,185 $0.00 2,185 $4.71
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
287,904 2025-12-03 No 4 M Direct
285,719 2025-12-03 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 926,604 Indirect By Wint2felden Holding SA
Footnotes
  1. These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2016.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.00 - $11.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4.
  3. This option shall vest as follows: 25% vested on December 4, 2016 and the remainder vests in quarterly installments over 3 years thereafter.